PTC Therapeutics, Inc. (NASDAQ: PTCT) Stock Competitors & Peer Comparison
See PTCT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PTCT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PTCT | $64.91 | +1.20% | 5.4B | -46.36 | -$1.40 | N/A |
| VRTX | $547.03 | -0.16% | 138.7B | 28.75 | $19.03 | N/A |
| MRNA | $248.69 | -0.85% | 100.6B | -30.51 | -$8.15 | N/A |
| REGN | $959.41 | +4.73% | 99.2B | 21.03 | $45.63 | +0.39% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $977.58 | +0.62% | 60.8B | 35.25 | $27.73 | N/A |
| ONC | $419.98 | -0.95% | 44.9B | 73.94 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $180.70 | -6.40% | 39.1B | -20.49 | -$8.82 | N/A |
| RVMDW | $8.65 | -13.59% | 37B | -0.98 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PTCT vs VRTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, VRTX has a market cap of 138.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while VRTX trades at $547.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas VRTX's P/E ratio is 28.75. In terms of profitability, PTCT's ROE is +0.57%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, PTCT is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
PTCT vs MRNA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MRNA has a market cap of 100.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MRNA trades at $248.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MRNA's P/E ratio is -30.51. In terms of profitability, PTCT's ROE is +0.57%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, PTCT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PTCT vs REGN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, REGN has a market cap of 99.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while REGN trades at $959.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas REGN's P/E ratio is 21.03. In terms of profitability, PTCT's ROE is +0.57%, compared to REGN's ROE of +0.15%. Regarding short-term risk, PTCT is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
PTCT vs VRNA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PTCT's ROE is +0.57%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, PTCT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
PTCT vs ARGX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ARGX has a market cap of 60.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ARGX trades at $977.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ARGX's P/E ratio is 35.25. In terms of profitability, PTCT's ROE is +0.57%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, PTCT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
PTCT vs ONC Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ONC has a market cap of 44.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ONC trades at $419.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ONC's P/E ratio is 73.94. In terms of profitability, PTCT's ROE is +0.57%, compared to ONC's ROE of +0.18%. Regarding short-term risk, PTCT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
PTCT vs SGEN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PTCT's ROE is +0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PTCT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PTCT vs RVMD Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RVMD trades at $180.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RVMD's P/E ratio is -20.49. In terms of profitability, PTCT's ROE is +0.57%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, PTCT is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PTCT vs RVMDW Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RVMDW has a market cap of 37B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RVMDW trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RVMDW's P/E ratio is -0.98. In terms of profitability, PTCT's ROE is +0.57%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, PTCT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
PTCT vs GMAB Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, GMAB has a market cap of 33.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while GMAB trades at $53.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas GMAB's P/E ratio is 40.60. In terms of profitability, PTCT's ROE is +0.57%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, PTCT is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PTCT vs ROIV Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ROIV has a market cap of 30.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ROIV trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ROIV's P/E ratio is -39.81. In terms of profitability, PTCT's ROE is +0.57%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, PTCT is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
PTCT vs INSM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, INSM has a market cap of 26.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while INSM trades at $120.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas INSM's P/E ratio is -42.82. In terms of profitability, PTCT's ROE is +0.57%, compared to INSM's ROE of -0.83%. Regarding short-term risk, PTCT is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PTCT vs UTHR Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, UTHR has a market cap of 25.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while UTHR trades at $595.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas UTHR's P/E ratio is 21.30. In terms of profitability, PTCT's ROE is +0.57%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PTCT is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
PTCT vs INCY Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, INCY has a market cap of 24.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while INCY trades at $122.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas INCY's P/E ratio is 16.43. In terms of profitability, PTCT's ROE is +0.57%, compared to INCY's ROE of +0.07%. Regarding short-term risk, PTCT is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
PTCT vs BNTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BNTX trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BNTX's P/E ratio is -11.37. In terms of profitability, PTCT's ROE is +0.57%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, PTCT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PTCT vs ALNY Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ALNY has a market cap of 21.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ALNY trades at $159.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ALNY's P/E ratio is 8.07. In terms of profitability, PTCT's ROE is +0.57%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, PTCT is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PTCT vs BGNE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PTCT's ROE is +0.57%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, PTCT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PTCT vs DNA-WT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PTCT's ROE is +0.57%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, PTCT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PTCT vs EXEL Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, EXEL has a market cap of 17.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while EXEL trades at $70.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas EXEL's P/E ratio is 20.20. In terms of profitability, PTCT's ROE is +0.57%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, PTCT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PTCT vs NBIX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while NBIX trades at $174.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas NBIX's P/E ratio is 25.20. In terms of profitability, PTCT's ROE is +0.57%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, PTCT is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PTCT vs ASND Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ASND trades at $259.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ASND's P/E ratio is -107.14. In terms of profitability, PTCT's ROE is +0.57%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PTCT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PTCT vs JAZZ Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while JAZZ trades at $248.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas JAZZ's P/E ratio is 9.26. In terms of profitability, PTCT's ROE is +0.57%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, PTCT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PTCT vs BBIO Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BBIO has a market cap of 15.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BBIO trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BBIO's P/E ratio is -26.16. In terms of profitability, PTCT's ROE is +0.57%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, PTCT is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PTCT vs SMMT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while SMMT trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas SMMT's P/E ratio is -14.86. In terms of profitability, PTCT's ROE is +0.57%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, PTCT is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PTCT vs KRTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PTCT's ROE is +0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PTCT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PTCT vs HALO Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, HALO has a market cap of 11.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while HALO trades at $101.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas HALO's P/E ratio is 18.97. In terms of profitability, PTCT's ROE is +0.57%, compared to HALO's ROE of +5.44%. Regarding short-term risk, PTCT is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check HALO's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PTCT vs KYMR Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, KYMR has a market cap of 11.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while KYMR trades at $134.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas KYMR's P/E ratio is -37.25. In terms of profitability, PTCT's ROE is +0.57%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PTCT is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check KYMR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PTCT vs TECH Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TECH's P/E ratio is 37.53. In terms of profitability, PTCT's ROE is +0.57%, compared to TECH's ROE of +0.08%. Regarding short-term risk, PTCT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PTCT vs BMRN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BMRN trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BMRN's P/E ratio is 28.04. In terms of profitability, PTCT's ROE is +0.57%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, PTCT is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PTCT vs RNAM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PTCT's ROE is +0.57%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, PTCT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check RNAM's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PTCT vs PCVX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, PCVX has a market cap of 10.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while PCVX trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas PCVX's P/E ratio is -8.99. In terms of profitability, PTCT's ROE is +0.57%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, PTCT is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PTCT vs SYRE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, SYRE has a market cap of 10.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while SYRE trades at $106.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas SYRE's P/E ratio is -54.78. In terms of profitability, PTCT's ROE is +0.57%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PTCT vs TGTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TGTX has a market cap of 10.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TGTX trades at $65.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TGTX's P/E ratio is 23.83. In terms of profitability, PTCT's ROE is +0.57%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, PTCT is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TGTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PTCT vs MDGL Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MDGL trades at $433.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MDGL's P/E ratio is -33.83. In terms of profitability, PTCT's ROE is +0.57%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, PTCT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check MDGL's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PTCT vs PRAX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, PRAX has a market cap of 9.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while PRAX trades at $346.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas PRAX's P/E ratio is -26.78. In terms of profitability, PTCT's ROE is +0.57%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, PTCT is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check PRAX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PTCT vs RXDX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PTCT's ROE is +0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PTCT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PTCT vs KRYS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while KRYS trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas KRYS's P/E ratio is 38.70. In terms of profitability, PTCT's ROE is +0.57%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, PTCT is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PTCT vs NUVL Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PTCT's ROE is +0.57%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PTCT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PTCT vs CRNX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PTCT's ROE is +0.57%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PTCT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PTCT vs PTGX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while PTGX trades at $134.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas PTGX's P/E ratio is 130.93. In terms of profitability, PTCT's ROE is +0.57%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, PTCT is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PTCT vs IMGN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PTCT's ROE is +0.57%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PTCT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check IMGN's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PTCT vs APGE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas APGE's P/E ratio is -31.19. In terms of profitability, PTCT's ROE is +0.57%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PTCT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PTCT vs BPMC Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PTCT's ROE is +0.57%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PTCT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PTCT vs CERE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CERE's P/E ratio is -16.47. In terms of profitability, PTCT's ROE is +0.57%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PTCT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PTCT vs CYTK Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CYTK trades at $58.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CYTK's P/E ratio is -8.11. In terms of profitability, PTCT's ROE is +0.57%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, PTCT is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check CYTK's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PTCT vs TWST Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TWST has a market cap of 8.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TWST trades at $122.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TWST's P/E ratio is -55.22. In terms of profitability, PTCT's ROE is +0.57%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TWST's competition here
Abivax S.A. (NASDAQ: ABVX)
PTCT vs ABVX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ABVX trades at $91.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ABVX's P/E ratio is -14.98. In terms of profitability, PTCT's ROE is +0.57%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, PTCT is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PTCT vs AXSM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, AXSM has a market cap of 7.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while AXSM trades at $149.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas AXSM's P/E ratio is -38.97. In terms of profitability, PTCT's ROE is +0.57%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, PTCT is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check AXSM's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PTCT vs RYTM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RYTM trades at $112.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RYTM's P/E ratio is -36.05. In terms of profitability, PTCT's ROE is +0.57%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, PTCT is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check RYTM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PTCT vs IMVT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while IMVT trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas IMVT's P/E ratio is -13.13. In terms of profitability, PTCT's ROE is +0.57%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, PTCT is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PTCT vs TXG Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TXG has a market cap of 7.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TXG trades at $62.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TXG's P/E ratio is -105.17. In terms of profitability, PTCT's ROE is +0.57%, compared to TXG's ROE of -0.08%. Regarding short-term risk, PTCT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TXG's competition here
Metsera, Inc. (NASDAQ: MTSR)
PTCT vs MTSR Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PTCT's ROE is +0.57%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, PTCT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PTCT vs IBRX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, IBRX has a market cap of 7.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while IBRX trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas IBRX's P/E ratio is -6.88. In terms of profitability, PTCT's ROE is +0.57%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, PTCT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check IBRX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
PTCT vs ORKA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ORKA trades at $107.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ORKA's P/E ratio is -55.24. In terms of profitability, PTCT's ROE is +0.57%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, PTCT is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ORKA's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PTCT vs ARWR Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ARWR has a market cap of 7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ARWR trades at $49.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ARWR's P/E ratio is -21.94. In terms of profitability, PTCT's ROE is +0.57%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PTCT is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ARWR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PTCT vs CAI Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CAI trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CAI's P/E ratio is 68.64. In terms of profitability, PTCT's ROE is +0.57%, compared to CAI's ROE of +0.16%. Regarding short-term risk, PTCT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check CAI's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
PTCT vs KOD Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, KOD has a market cap of 6.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while KOD trades at $109.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas KOD's P/E ratio is -26.22. In terms of profitability, PTCT's ROE is +0.57%, compared to KOD's ROE of -2.73%. Regarding short-term risk, PTCT is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
PTCT vs MRUS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PTCT's ROE is +0.57%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, PTCT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PTCT vs ACLX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PTCT's ROE is +0.57%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, PTCT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PTCT vs RETA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RETA's P/E ratio is -66.29. In terms of profitability, PTCT's ROE is +0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PTCT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check RETA's competition here
Veradermics, Incorporated (NYSE: MANE)
PTCT vs MANE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MANE has a market cap of 6.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MANE trades at $156.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MANE's P/E ratio is -49.73. In terms of profitability, PTCT's ROE is +0.57%, compared to MANE's ROE of -0.20%. Regarding short-term risk, PTCT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
PTCT vs CGON Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CGON trades at $72.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CGON's P/E ratio is -26.99. In terms of profitability, PTCT's ROE is +0.57%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PTCT is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PTCT vs LGND Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while LGND trades at $316.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas LGND's P/E ratio is 34.78. In terms of profitability, PTCT's ROE is +0.57%, compared to LGND's ROE of +0.05%. Regarding short-term risk, PTCT is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PTCT vs BLTE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while BLTE trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas BLTE's P/E ratio is -83.39. In terms of profitability, PTCT's ROE is +0.57%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PTCT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PTCT vs CNTA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PTCT's ROE is +0.57%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PTCT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PTCT vs MIRM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MIRM trades at $94.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MIRM's P/E ratio is -6.50. In terms of profitability, PTCT's ROE is +0.57%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, PTCT is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PTCT vs TERN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TERN's P/E ratio is -51.41. In terms of profitability, PTCT's ROE is +0.57%, compared to TERN's ROE of -0.14%. Regarding short-term risk, PTCT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check TERN's competition here
Erasca, Inc. (NASDAQ: ERAS)
PTCT vs ERAS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ERAS trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ERAS's P/E ratio is -18.06. In terms of profitability, PTCT's ROE is +0.57%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PTCT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PTCT vs SRRK Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while SRRK trades at $46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas SRRK's P/E ratio is -13.51. In terms of profitability, PTCT's ROE is +0.57%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, PTCT is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PTCT vs CDTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PTCT's ROE is +0.57%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, PTCT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
PTCT vs ABCM Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PTCT's ROE is +0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PTCT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PTCT vs ISEE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PTCT's ROE is +0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PTCT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PTCT vs APLS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas APLS's P/E ratio is 38.35. In terms of profitability, PTCT's ROE is +0.57%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PTCT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check APLS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PTCT vs EWTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, EWTX has a market cap of 5.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while EWTX trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas EWTX's P/E ratio is -25.71. In terms of profitability, PTCT's ROE is +0.57%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, PTCT is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check EWTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PTCT vs COGT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while COGT trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas COGT's P/E ratio is -13.93. In terms of profitability, PTCT's ROE is +0.57%, compared to COGT's ROE of -0.71%. Regarding short-term risk, PTCT is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check COGT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PTCT vs DNTH Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while DNTH trades at $89.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas DNTH's P/E ratio is -21.52. In terms of profitability, PTCT's ROE is +0.57%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PTCT is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PTCT vs TVTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TVTX trades at $52.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TVTX's P/E ratio is -115.64. In terms of profitability, PTCT's ROE is +0.57%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, PTCT is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TVTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PTCT vs ADPT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ADPT trades at $29.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ADPT's P/E ratio is -73.02. In terms of profitability, PTCT's ROE is +0.57%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, PTCT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ADPT's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PTCT vs IONS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, IONS has a market cap of 4.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while IONS trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas IONS's P/E ratio is -8.66. In terms of profitability, PTCT's ROE is +0.57%, compared to IONS's ROE of -1.20%. Regarding short-term risk, PTCT is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check IONS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PTCT vs DFTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while DFTX trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas DFTX's P/E ratio is N/A. In terms of profitability, PTCT's ROE is +0.57%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, PTCT is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PTCT vs FOLD Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PTCT's ROE is +0.57%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, PTCT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PTCT vs AKRO Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PTCT's ROE is +0.57%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, PTCT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PTCT vs ALPN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PTCT's ROE is +0.57%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PTCT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check ALPN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PTCT vs CRSP Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CRSP trades at $45.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CRSP's P/E ratio is -9.61. In terms of profitability, PTCT's ROE is +0.57%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, PTCT is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
PTCT vs RLAY Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RLAY trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RLAY's P/E ratio is -12.56. In terms of profitability, PTCT's ROE is +0.57%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, PTCT is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check RLAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
PTCT vs TNGX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TNGX trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TNGX's P/E ratio is -31.00. In terms of profitability, PTCT's ROE is +0.57%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
PTCT vs OPT Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas OPT's P/E ratio is -1.52. In terms of profitability, PTCT's ROE is +0.57%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PTCT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
PTCT vs PRTC Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas PRTC's P/E ratio is -3.78. In terms of profitability, PTCT's ROE is +0.57%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, PTCT is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check PRTC's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PTCT vs XENE Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while XENE trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas XENE's P/E ratio is -8.96. In terms of profitability, PTCT's ROE is +0.57%, compared to XENE's ROE of -0.40%. Regarding short-term risk, PTCT is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check XENE's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PTCT vs MRTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PTCT's ROE is +0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PTCT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check MRTX's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
PTCT vs AMLX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, AMLX has a market cap of 4.1B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while AMLX trades at $31.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas AMLX's P/E ratio is -21.20. In terms of profitability, PTCT's ROE is +0.57%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, PTCT is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check AMLX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
PTCT vs ABCL Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ABCL trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ABCL's P/E ratio is -22.13. In terms of profitability, PTCT's ROE is +0.57%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, PTCT is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PTCT vs CPRX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CPRX's P/E ratio is 17.49. In terms of profitability, PTCT's ROE is +0.57%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PTCT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CPRX's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
PTCT vs TARS Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, TARS has a market cap of 3.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while TARS trades at $76.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas TARS's P/E ratio is -70.42. In terms of profitability, PTCT's ROE is +0.57%, compared to TARS's ROE of -2.46%. Regarding short-term risk, PTCT is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check TARS's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
PTCT vs ELVN Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while ELVN trades at $51.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas ELVN's P/E ratio is -30.65. In terms of profitability, PTCT's ROE is +0.57%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, PTCT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PTCT vs RYZB Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PTCT's ROE is +0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PTCT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check RYZB's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
PTCT vs IOVA Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, IOVA has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while IOVA trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas IOVA's P/E ratio is -11.08. In terms of profitability, PTCT's ROE is +0.57%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, PTCT is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check IOVA's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PTCT vs CBAY Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PTCT's ROE is +0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PTCT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PTCT.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
PTCT vs VKTX Comparison November 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTCT stands at 5.4B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, PTCT is priced at $64.91 on the NASDAQ, while VKTX trades at $28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTCT currently has a P/E ratio of -46.36, whereas VKTX's P/E ratio is -5.27. In terms of profitability, PTCT's ROE is +0.57%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, PTCT is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for PTCT.Check VKTX's competition here